Fernando Suarez Saiz

Fernando Suarez Saiz

Auto-generated profile, based on publicly available information

Fernando Suarez Saiz

IBM Watson Health, New York, NY

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2007 in Leukemia
Verified
Journal Article
Open access
PDF file
LYL Yang
L Yang
YHY Han
Y Han
FSF Saurez Saiz
F Saurez Saiz
MMM D Minden
M D Minden
The Wilms' tumor 1 (WT1) gene encodes a transcription factor important for normal cellular development and cell survival. The initial discovery of WT1 as the causative gene in an autosomal-recessive condition identified it as a tumor suppressor gene whose mutations are associated with urogenital disease and the development of kidney tumors. However, this view is not in keeping with the frequent finding of wild-type, full-length WT1 in human leukemia, breast cancer and several other cancers including the majority of Wilms' tumors. Rather, these observations suggest that in those conditions, WT1 has an oncogenic role in tumor formation. In this review, we explore the literature supporting both views of WT1 in human cancer and in particular human leukemias. To understand the mechanism by which WT1 can do this, we will also examine its functional activity as a transcription factor and the influence of protein partners on its dual behavior.

1 February 2012 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
RMRichard Marcotte
Richard Marcotte
KBKevin R. Brown
Kevin R. Brown
FSFernando Suarez
Fernando Suarez
ASAzin Sayad
Azin Sayad
KKKonstantina Karamboulas
Konstantina Karamboulas
JMJason Moffat
Jason Moffat
Genomic analyses are yielding a host of new information on the multiple genetic abnormalities associated with specific types of cancer. A comprehensive description of cancer-associated genetic abnormalities can improve our ability to classify tumors into clinically relevant subgroups and, on occasion, identify mutant genes that drive the cancer phenotype (“drivers”). More often, though, the functional significance of cancer-associated mutations is difficult to discern. Genome-wide pooled short hairpin RNA (shRNA) screens enable global identification of the genes essential for cancer cell survival and proliferation, providing a “functional genomic” map of human cancer to complement genomic studies. Using a lentiviral shRNA library targeting ∼16,000 genes and a newly developed, dynamic scoring approach, we identified essential gene profiles in 72 breast, pancreatic, and ovarian cancer cell lines. Integrating our results with current and future genomic data should facilitate the systematic identification of drivers, unanticipated synthetic lethal relationships, and functional vulnerabilities of these tumor types. Significance: This study presents a resource of genome-scale, pooled shRNA screens for 72 breast, pancreatic, and ovarian cancer cell lines that will serve as a functional complement to genomics data, facilitate construction of essential gene profiles, help uncover synthetic lethal relationships, and identify uncharacterized genetic vulnerabilities in these tumor types. Cancer Discovery; 2(2); 172–89. © 2011 AACR. This article is highlighted in the In This Issue feature, p. 95.

1 November 2008 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
TWTabitha E. Wood
Tabitha E. Wood
SDShadi Dalili
Shadi Dalili
CSCraig D. Simpson
Craig D. Simpson
RHRose Hurren
Rose Hurren
XMXinliang Mao
Xinliang Mao
ASAaron Schimmer
Aaron Schimmer
Evasion of death receptor ligand-induced apoptosis is an important contributor to cancer development and progression. Therefore, molecules that restore sensitivity to death receptor stimuli would be important tools to better understand this biological pathway and potential leads for therapeutic adjuncts. Previously, the small-molecule N-[4-chloro-3-(trifluoromethyl)phenyl]-3-oxobutanamide (fasentin) was identified as a chemical sensitizer to the death receptor stimuli FAS and tumor necrosis factor apoptosis-inducing ligand, but its mechanism of action was unknown. Here, we determined that fasentin alters expression of genes associated with nutrient and glucose deprivation. Consistent with this finding, culturing cells in low-glucose medium recapitulated the effects of fasentin and sensitized cells to FAS. Moreover, we showed that fasentin inhibited glucose uptake. Using virtual docking studies with a homology model of the glucose transport protein GLUT1, fasentin interacted with a unique site in the intracellular channel of this protein. Additional chemical studies with other GLUT inhibitors and analogues of fasentin supported a role for partial inhibition of glucose transport as a mechanism to sensitize cells to death receptor stimuli. Thus, fasentin is a novel inhibitor of glucose transport that blocks glucose uptake and highlights a new mechanism to sensitize cells to death ligands. [Mol Cancer Ther 2008;7(11):3546–55]

1 March 2012 in Molecular Cell
Verified
Journal Article
Closed access
DMDavid Meiri
David Meiri
CMChristopher Marshall
Christopher Marshall
MGMelissa A. Greeve
Melissa A. Greeve
BKBryan Kim
Bryan Kim
MBMarc Balan
Marc Balan
RRRobert Rottapel
Robert Rottapel

1 January 2010 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
TWTabitha E. Wood
Tabitha E. Wood
SDShadi Dalili
Shadi Dalili
CSCraig D. Simpson
Craig D. Simpson
MSMahadeo A. Sukhai
Mahadeo A. Sukhai
RHRose Hurren
Rose Hurren
ASAaron Schimmer
Aaron Schimmer
Evasion of death receptor ligand–induced apoptosis represents an important contributor to cancer development and progression. Therefore, molecules that restore sensitivity to death receptor stimuli would be important tools to better understand this biological pathway and potential leads for therapeutic adjuncts. Previously, the small-molecule 4-(4-chloro-2-methylphenoxy)-N-hydroxybutanamide (that we propose be named droxinostat) was identified as a chemical sensitizer to death receptor stimuli, decreasing the expression of the caspase-8 inhibitor FLIP. However, the direct targets of droxinostat were unknown. To better understand the mechanism of action of droxinostat and highlight new strategies to restore sensitivity to death receptor ligands, we analyzed changes in gene expression using the Connectivity Map after treating cells with droxinostat. Changes in gene expression after droxinostat treatment resembled changes observed after treatment with histone deacetylase (HDAC) inhibitors. Therefore, we examined the effects of droxinostat on HDAC activity and showed that it selectively inhibited HDAC3, HDAC6, and HDAC8 and that inhibition of these HDACs was functionally important for its ability to sensitize cells to death ligands. Thus, we have identified a selective HDAC inhibitor and showed that selective HDAC inhibition sensitizes cells to death ligands, thereby highlighting a new mechanism to overcome resistance to death receptor ligands. Mol Cancer Ther; 9(1); 246–56

5 May 2005 in Leukemia
Verified
Journal Article
Closed access
PDF file
MTM R Trus
M R Trus
LYL Yang
L Yang
FSF Suarez Saiz
F Suarez Saiz
LBLouise Bordeleau Louise Bordeleau
Louise Bordeleau Louise Bordeleau
IJI Jurisica
I Jurisica
MMM D Minden
M D Minden